Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company based in Bethesda, MD, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development.

In January 2006, Sucampo received marketing approval from the U.S. Food and Drug Administration for its first product, AMITIZAŽ (lubiprostone) (24 mcg).

 

Feb 2, 2012
Lubiprostone Meets Primary Endpoint in Phase 3 Clinical Trial for Opioid-Induced Bowel Dysfunction (OBD)

Dec 22, 2011
Sucampo Reports Conclusion of Arbitration Hearing

Dec 8, 2011
Sucampo Promotes Birgit Roerig, Ph.D. to Vice President, Pharmacology and Toxicology